Abstract
For decades, bovine jugular vein conduits (BJV) and classic cryopreserved homografts have been the two most widely used options for pulmonary valve replacement (PVR) in congenital heart disease. More recently, decellularized pulmonary homografts (DPH) have provided an alternative avenue for PVR. Matched comparison of patients who received DPH for PVR with patients who received bovine jugular vein conduits (BJV) considering patient age group, type of heart defect, and previous procedures. 319 DPH patients were matched to 319 BJV patients; the mean age of BJV patients was 15.3 (SD 9.5) years versus 19.1 (12.4) years in DPH patients (p = 0.001). The mean conduit diameter was 24.5 (3.5) mm for DPH and 20.3 (2.5) mm for BJV (p < 0.001). There was no difference in survival rates between the two groups after 10 years (97.0 vs. 98.1%, p = 0.45). The rate of freedom from endocarditis was significantly lower for BJV patients (87.1 vs. 96.5%, p = 0.006). Freedom from explantation was significantly lower for BJV at 10 years (81.7 vs. 95.5%, p = 0.001) as well as freedom from any significant degeneration at 10 years (39.6 vs. 65.4%, p < 0.001). 140 Patients, matched for age, heart defect type, prior procedures, and conduit sizes of 20–22 mm (± 2 mm), were compared separately; mean age BJV 8.7 (4.9) and DPH 9.5 (7.3) years (p = n.s.). DPH showed 20% higher freedom from explantation and degeneration in this subgroup (p = 0.232). Decellularized pulmonary homografts exhibit superior 10-year results to bovine jugular vein conduits in PVR.
Similar content being viewed by others
Introduction
In 2002, a glutaraldehyde cross-linked, heterologous bovine jugular vein conduit with a competent tri-leaflet venous valve was granted humanitarian use device (HUD) designation by the U.S. Food and Drug Administration. (Contegra Pulmonary Valved Conduit FDA Executive Summary 2020) Non-randomized multi-centre trials performed in the U.S. and Europe showed good results for this product, Contegra®, and identified several issues, such as distal graft stenosis, which were subsequently addressed by increased rinsing and modified suturing. (Boethig et al. 2012; Breymann et al. 2009) Numerous publications have described good results for bovine jugular vein (BJV) conduits when used for pulmonary valve replacement (PVR). Interestingly, Contegra is one of the very few products in cardiovascular medicine which is licensed only for paediatric use. It is nevertheless also used extensively for adults and has shown good results for this indication. (Boethig et al. 2009) There, however, is a size limitation for BJV in adults as the device is available in 6 sizes in even increments between 12 and 22 mm inside diameter, measured at the inflow end.
BJV and classic cryopreserved homografts (CH) have been the two most widely used options for pulmonary valve replacement (PVR) in congenital heart disease over the last two decades. Comparisons of Contegra® with CH have been reported on in a multitude of publications and BJV have shown similar, but slightly inferior results in most studies. (Marathe et al. 2021; Patel et al. 2020; Sandica et al. 2016; Yong et al. 2015) As a consequence, cryopreserved homografts have continued to be viewed by the majority of cardiac surgeons as the gold standard.
In 2013, fresh non-cryopreserved decellularized homografts were approved for use in pulmonary valve replacement by the Paul-Ehrlich-Institute, the German authority for human tissue-based devices. Five-year data from European-wide ESPOIR-trial, which started in 2014, showed excellent performance for decellularized pulmonary homografts (DPH) and low rates of adverse events. ESPOIR Registry data, covering a period of up to 15 years and including a matched comparison with CH, demonstrated statistically significant superior freedom from explantation and less dysfunction. (Bobylev et al. 2022).
The long-term durability of any biological conduit for pulmonary valve replacement depends on the age of the recipient, as immune response is increased in children, and also the type of congenital heart defect. (Khanna et al. 2015) PVR in an anatomical position, such as in the Ross procedure, has shown superior durability compared with extra-anatomical conduits. (Meijer et al. 2019) It also has been shown that a suboptimal outcome in the immediate postoperative phase, will result in lower freedom from re-intervention, even when the residual gradient or regurgitation is mild. (Bokma et al. 2015) Suboptimal surgical results are far more likely in re-do procedures.
The aim of this study is a matched comparison of bovine jugular vein conduits and decellularized homografts considering patient age, type of congenital heart defect, and the number of previous heart operations.
Materials and methods
Cohorts for matching
Patients who had received a decellularized pulmonary homograft (DPH) were recruited from the ESPOIR Registry. The registry aims to provide follow-up on all patients receiving DPH processed by corlife oHG (www.corlife.eu), a Hannover-based biotechnology company which provides decellularization as a service to tissue establishments. At the time of this analysis, the registry contained data on 361 DPH patients, amounting to approximately 90% of all processed DPH which have been implanted to date, including 121 patients from the prospective ESPOIR trial. Recently, the 5-year results of this trial were published including a comparison of decellularized fresh homografts with conventional cryopreserved homografts based on the above-mentioned registry data. (Bobylev et al. 2022).
BJV patients for matching were chosen from the updated RVOT Conduit Registry (Sandica et al. 2016). Matching was performed on the basis of the patient’s age category at implantation, the type of congenital heart defect, the number of previous operations, and the number of previous PVR. In 42 out of the 361 total patients with DPH, no match was found within the RVOT Conduit Registry, which reduced the number of DPH patients to be analysed to 319 for whom matches were available.
56% of all patient data sets analysed were derived from the seven centres participating in the ESPOIR trial; the remaining were derived from seven additional centres participating in the RVOT Registry. BJV patients were younger to a statistically significant degree due to the upper size limit of 22 mm of BJV. Therefore, an additional comparison was performed in patients who were additionally matched for conduit size. For this comparison, only matched patients with conduit sizes of 20–22 mm (± 2 mm) were included.
A peak echocardiographic gradient of ≥ 50 mmHg and regurgitation grade ≥ moderate was defined as dysfunctional.
The ESPOIR trial was registered under ClinicalTrials.gov, NCT 02,035,540, and results have been published at the respective ClinicalTrials.gov website. Approval was given by all local ethics committees (22.10.2013, No. 2016/2013) before the start of the study, and informed consent was obtained appropriately from all participants or parents.
Statistics
Summaries of the numeric data are given as means and standard deviation. The Mann–Whitney U test for non-paired samples was used for data with skewed distribution. Time-related events, such as freedom from explantation and endocarditis, were evaluated according to Kaplan–Meier, including numbers at risk at 0, 5 and 10 years, as well as freedom-from-event rates at 0, 5 and 10 years, with their respective 95% confidence limits.
The proportion of explanted and dysfunctional grafts over time was calculated for the two valve grafts as described above, with linear interpolation of the numerical values for peak gradients and insufficiency grades. The yearly status fractions were multiplied with the explantation rates observed at the end of the entire post-implantation rates. 3 The Kruskall-Wallis-test for independent samples with sorted hypotheses was applied to compare the fractions of intact conduits.
SPSS 23 (IBM Corporation, Somer, NY) was used for the analyses. No correction for multiple testing was performed. All the statistical tests were two-sided and a probability p-value of 0.05 or less was considered statistically significant.
Results
Outcome comparison of DPH recipients with matched bovine jugular vein conduit patients
319 DPH patients were matched to 319 BJV patients: the mean age of BJV patients was 15.3 (SD 9.5) years versus 19.1 (SD 12.4) years in DPH patients (p = 0.001). The mean conduit diameter of DPH was 24.5 (SD 3.5) mm and 20.3 (SD 2.5) mm for BJV (p < 0.001).
Table 1 provides details for the two study cohorts.
There was no difference in survival rates for the two groups after 10 years (97.0 vs. 98.1%,p = 0.45). The rate of freedom from endocarditis was significantly lower for BJV patients (87.1 vs. 96.5%, p = 0.006). Freedom from explantation was also significantly lower for BJV at 10 years (81.7 vs. 95.5%, p = 0.001) as was freedom from any significant degeneration at 10 years (39.6 vs. 65.4%, p < 0.001).
Table 2 summarizes the specific results for each conduit type at 5 and 10 years.
Figure 1 and 2 provide Kaplan–Meier analyses for freedom from death, endocarditis, conduit-related catheter interventions, explantation, catheter valve implantation, stenosis, regurgitation, as well as freedom from combined degeneration and explantation.
Figure 3 gives an overview of freedom from explantation and the current functional status of the remaining conduits within the two matched groups. Yearly summarized fractions of intact DPHs during all the commonly observed years were statistically significantly larger than the corresponding fractions of BJV (p = 0.025).
Outcome comparison of DPH and BJV according to conduit size
140 Patients matched for age, heart defect, prior procedures and conduit sizes of 20–22 mm (± 2 mm) were compared in a separate analysis. Figures 4 and 5 provide Kaplan–Meier analyses for freedom from death, endocarditis, conduit-related catheter interventions, explantation, catheter valve implantation, stenosis, regurgitation, as well as freedom from combined degeneration and explantation. DPH showed 20% higher freedom from explantation and degeneration for DPH in this subgroup (p = 0.232). Table 3 provides details for these two sub-cohorts.
Discussion
Bovine jugular vein conduits have together with cryopreserved homografts traditionally been the two main options for PVR with comparable performance. From a surgical viewpoint the intraoperative handling of both grafts is comparable as outlined by a publication from Wauthy et al., which found no statistically significant difference in the operative data for anesthesia, surgery, cardiopulmonary bypass, and aortic clamping durations. (Poinot et al. 2018).
We have shown the results of decellularized pulmonary homografts to be superior to those obtained in classic cryopreserved homografts for this indication using the 5-year results of the prospective multi-center ESPOIR trial and long-term data from the ESPOIR Registry in a matched comparison. (Bobylev et al. 2022) A recent meta-analysis confirmed significantly lower re-operation rates for decellularized homografts than for conventional cryopreserved homografts. Importantly, this meta-analysis used data from studies with different decellularization protocols. (Waqanivavalagi et al. 2020).
Within the present analysis, we demonstrate that results for decellularized pulmonary homografts (DPH) also indicate better performance than the results of bovine jugular vein conduits (BJV). The most notable difference may be the significantly higher freedom from endocarditis and the higher freedom from reoperation in matched patient cohorts. While one can argue that the two cohorts were not perfectly matched as Contegra® patients were younger, we do show that DPH resulted in about 20% better freedom from explantation and valve degeneration in exactly the same conduit sizes. The lack of statistical significance can be explained by the relatively low patient numbers in this subgroup analysis.
Fortunately, no difference was found in survival rates, which could be attributed to the robust monitoring system in Europe following surgery for congenital heart defects and experience with timely re-interventions. Endocarditis, however, showed significant differences with about 10% more patients affected after 10 years following BJV implantation. This result is corroborated by two recent nationwide registry-based analyses in Denmark and Germany, which found the risk for endocarditis in Contegra® and Melody® to be about five-to-six times higher than following pulmonary valve replacement using homografts (hazard ratios 6.72 and 5.49, p < 0.001, (Stammnitz et al. 2022)). This is a dramatic finding and has yet to be included in guideline recommendations. In our view, patients with an increased risk for infective endocarditis should not receive BJV in surgical or catheter-based procedures in view of the considerable morbidity and mortality rates. (Abdelghani et al. 2018 ).
The main advantage of valved bovine jugular vein (BJV) conduits over valved allografts is their better availability, as these prostheses do not rely on the complex pathway of human tissue donation. This holds especially true for the smaller sized grafts needed for pulmonary valve replacement in children and BJV have shown similar results to crypopreserved homografts when used in newborns, infants, and small children.(Fiore et al. 2010) Some surgeons attribute this to the tendency of BJV to dilate, which allows for slightly longer freedom from reoperation. Unfortunately, the number of small DPH in this analysis was limited and did not allow for a robust statistical comparison to small-sized BJV. Hopefully, this comparison can be performed in the future as more tissue banks increasingly recognize the benefits of decellularization. (Jashari 2021).
Despite the better performance of DPH, these grafts can still elicit an immune response which may be stronger in younger patients. In decellularized aortic homografts there were markedly better results in adult recipients. (Horke et al. 2020) We have shown the high levels of variance in the binding of preformed antibodies to different homogenized decellularized homograft samples in healthy controls, which inspired the idea of pre-operative matching algorithms to improve results in younger patients. (Ebken et al. 2021) We are currently analyzing the humoral immune response towards decellularized homografts in patients pre-and postoperatively, with the aim of developing early screening methods for immunological activation.
At the same time, very little is known about the immunological mechanisms involved in BJV failure and there is sparse literature focusing on this aspect. Xenogenic tissue will elicit a strong immune response, which may be mitigated by glutaraldehyde cross-linking, but not eliminated. (Williams et al. 2021) Decellularized xenogenic tissues still elicit a strong immune response and this has led to dramatic clinical consequences. (Simon et al. 2003) Therefore, a possible option could be the combination of decellularization and cross-linking of xenogenic tissue. (Williams et al. 2021) Genetically modified animal sources may further allow for improved clinical performance of xenogenic tissues in general in the future. (Ramm et al. 2021).
Overall, bovine jugular vein conduits fare well when used for pulmonary valve replacement as indicated by a very low 10-year mortality. However, results for decellularized pulmonary homografts show better performance. Given the limited availability of human tissue, further research on xenogenic grafts seems inevitable but also promising in view of recent advances made in the genetic engineering of animals.
Limitations
The restrictions inherent in the matching process as a result of low numbers and high variance in congenital heart defects are the main limitations of this analysis.
Only retrospectively collected data was available for BJV with, at times, incomplete data in echocardiographic reports. However, this would be more likely to lead to an underestimation of valve degeneration and other adverse events in the BJV cohort in comparison with the prospective follow-up for DPH patients.
Conclusion
Decellularized pulmonary homografts exhibit better results than bovine jugular vein conduits in pulmonary valve replacement. Freedom from explantation in matched cohorts was higher for decellularized homografts due to less degeneration. Freedom from endocarditis was significantly reduced in bovine jugular vein conduits.
Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.
Abbreviations
- BJV:
-
Bovine jugular vein
- CH:
-
Cryopreserved homograft
- DORV:
-
Double outlet right ventricle
- DPH:
-
Decellularized pulmonary homograft
- HUD:
-
Humanitarian use device
- PA:
-
Pulmonary atresia
- PI:
-
Pulmonary insufficiency
- PS:
-
Pulmonary stenosis
- PVR:
-
Pulmonary valve replacement
- RVOT:
-
Right ventricular outflow tract
- SD:
-
Standard deviation
- TAC:
-
Truncus arteriosus communis
- TGA:
-
Transposition of great arteries
- TOF:
-
Tetralogy of Fallot
References
Abdelghani M, Nassif M, Blom NA, Van Mourik MS, Straver B, Koolbergen DR et al (2018) Infective endocarditis after melody valve implantation in the pulmonary position: a systematic review. J Am Heart Assoc 7:e008163
Bobylev D, Horke A, Boethig D, Hazekamp M, Meyns B, Rega F et al (2022) 5-Year results from the prospective European multi-centre study on decellularized homografts for pulmonary valve replacement ESPOIR Trial and ESPOIR Registry data. Eur J Cardiothorac Surg 62(5):ezac219
Boethig D, Westhoff-Bleck M, Hecker H, Ono M, Goerler A, Sarikouch S et al (2009) Bovine jugular veins in the pulmonary position in adults – 5 years’ experience with 64 implantations. Thorac Cardiovasc Surg 57:196–201
Boethig D, Schreiber C, Hazekamp M, Blanz U, Pretre R, Asfour B et al (2012) Risk factors for distal Contegra stenosis: results of a prospective European multicentre study. Thorac Cardiovasc Surg 60:195–204
Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG et al (2015) Individualised prediction of pulmonary homograft durability in tetralogy of Fallot. Heart 101:1717–1723
Breymann T, Blanz U, Wojtalik MA, Daenen W, Hetzer R, Sarris G et al (2009) European Contegra multicentre study: 7-year results after 165 valved bovine jugular vein graft implantations. Thorac Cardiovasc Surg 57:257–269
Contegra pulmonary valved conduit FDA executive summary. 2020 FDA Pediatric advisory committee meeting. Last accessed 05.07.2022
Ebken JMN, Smart I, Ramm R, Goecke T, Jashari R, Böthig D, Horke A, Cebotari S, Tudorache I, Avsar M, Bobylev D, Haverich A, Sarikouch S, Hilfiker A (2021) Residual immune response towards decellularized homografts may be highly individual. Eur J Cardiothorac Surg 59(4):773–782
Fiore AC, Ruzmetov M, Huynh D, Hanley S, Rodefeld MD, Turrentine MW et al (2010) Comparison of bovine jugular vein with pulmonary homograft conduits in children less than 2 years of age. Eur J Cardio-Thorac 38:318–325
Horke A, Bobylev D, Avsar M, Meyns B, Rega F, Hazekamp M et al (2020) Paediatric aortic valve replacement using decellularized allografts. Eur J Cardiothorac Surg 58(4):817–824
Jashari R (2021) Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives. Cell Tissue Bank 22(4):519–537
Khanna AD, Hill KD, Pasquali SK, Wallace AS, Masoudi FA, Jacobs ML et al (2015) Benchmark outcomes for pulmonary valve replacement using the society of thoracic surgeons databases. Ann Thorac Surg 100:138–145
Marathe SP, Hussein N, Wallace FRO, Bell D, Yong M, Betts KS et al (2021) Comparison of homografts and bovine jugular vein conduits in the pulmonary position in patients <20 years of age. J Thorac Cardiovasc Surg 164:752–762
Meijer FMM, Kies P, Jongbloed MRM, Hazekamp MG, Koolbergen DR, Blom NA et al (2019) Excellent durability of homografts in pulmonary position analysed in a predefined adult group with tetralogy of Fallot. Interact Cardiovasc Thorac Surg 28:279–283
Patel PM, Herrmann JL, Rodefeld MD, Turrentine MW, Brown JW (2020) Bovine jugular vein conduit versus pulmonary homograft in the ross operation. Cardiol Young 30:323–327
Poinot N, Fils JF, Demanet H, Dessy H, Biarent D, Wauthy P (2018) Pulmonary valve replacement after right ventricular outflow tract reconstruction with homograft vs Contegra(R): a case control comparison of mortality and morbidity. J Cardiothorac Surg 13:8
Ramm R, Goecke T, Köhler P, Tudorache I, Cebotari S, Ciubotaru A, Sarikouch S, Höffler K, Bothe F, Petersen B, Haverich A, Niemann H, Hilfiker A (2021) Immunological and functional features of decellularized xenogenic heart valves after transplantation into GGTA1-KO pigs. Regen Biomat 8:036
Sandica E, Boethig D, Blanz U, Goerg R, Haas NA, Laser KT et al (2016) bovine jugular veins versus homografts in the pulmonary position: an analysis across two centers and 711 patients-conventional comparisons and time status graphs as a new approach. Thorac Cardiovasc Surg 64:25–35
Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U et al (2003) Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 23:1002–1006
Stammnitz C, Huscher D, Bauer UMM, Urban A, Nordmeyer J, Schubert S et al (2022) Nationwide registry-based analysis of infective endocarditis risk after pulmonary valve replacement. J Am Heart Assoc 11:e022231
Waqanivavalagi S, Bhat S, Ground MB, Milsom PF, Cornish J (2020) Clinical performance of decellularized heart valves versus standard tissue conduits: a systematic review and meta-analysis. J Cardiothorac Surg 15:260
Williams DF, Bezuidenhout D, de Villiers J, Human P, Zilla P (2021) Long-term stability and biocompatibility of pericardial bioprosthetic heart valves. Front Cardiovasc Med 8:728577
Yong MS, Yim D, d’Udekem Y, Brizard CP, Robertson T, Galati JC et al (2015) Medium-term outcomes of bovine jugular vein graft and homograft conduits in children. ANZ J Surg 85:381–385
Acknowledgements
The authors specifically thank the participating tissue banks and hospitals with their respective study team members for their support in continuation of this study. The authors are also grateful to the following individuals and their organizations for contributing to the RVOT Registry: J.v. Puyvelde, E. Sandica, Ch. Sebening, N. Doll, R. Cesnjevar, R. Goerg, T. Loukanov, W. Hemmer, A. Rüffer. The authors also thank Nina McGuinness for editorial assistance.
Funding
Open Access funding enabled and organized by Projekt DEAL. This study was supported by a grant from the European Union’s Seventh Framework Programme for Research, Technological Development and Demonstration under Grant Agreement No. 278453. Data collection was also supported by CORTISS GmbH, a Hannover-based non-profit organisation for cardiovascular research (www.cortiss.de), Kleine Herzen Westerwald e.V. (www.kleine-herzen-westerwald.de), a patient organisation for congenital heart defects in children, and by the participating institutions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
AH holds shares in corlife oHG, the company providing the service of processing decellularized allografts used in this study. RJ is Director of the European Homograft Bank. Martin Andreas has received institutional research funding (Edwards, Abbott, Medtronic, LSI), and has served as a proctor/speaker/consultant (Edwards, Abbott, Medtronic, Boston, Zoll). Guenther Laufer has received consulting fees from Edwards Lifesciences. All other authors declare that there are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bobylev, D., Horke, A., Avsar, M. et al. Matched comparison of decellularized homografts and bovine jugular vein conduits for pulmonary valve replacement in congenital heart disease. Cell Tissue Bank 25, 55–66 (2024). https://doi.org/10.1007/s10561-023-10082-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-023-10082-4